Brief: Index Pharmaceuticals Meets Primary Endpoint In Phase IIb Study CONDUCT With Cobitolimod In Ulcerative Colitis

Flerie AB

27/08/2019 06:15

Aug 27 (Reuters) - InDex Pharmaceuticals Holding AB
 INDEX.ST :
    * INDEX PHARMACEUTICALS MEETS PRIMARY ENDPOINT IN THE PHASE
IIB
STUDY CONDUCT WITH COBITOLIMOD IN ULCERATIVE COLITIS
    * STUDY MET PRIMARY ENDPOINT OF CLINICAL REMISSION,
DEMONSTRATING
A SUPERIOR EFFICACY OF 15% (DELTA) IN PATIENTS RECEIVING HIGHEST
DOSE OF COBITOLIMOD COMPARED TO PLACEBO
    * 15% DELTA VERSUS. PLACEBO FOR CLINICAL REMISSION
    * POSITIVE TOP LINE RESULTS FROM DOSE OPTIMISATION STUDY
CONDUCT,
WHICH IS EVALUATING COBITOLIMOD FOR TREATMENT OF MODERATE TO
SEVERE ULCERATIVE COLITIS

Source text for Eikon:  ID:nWkr5T8QZl 
Further company coverage:  INDEX.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))